• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

垂体腺瘤中基于天然产物和微小RNA的方法:揭示治疗干预措施

Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention.

作者信息

Aboregela Adel Mohamed

机构信息

Anatomy Department, College of Medicine, University of Bisha, P.O Box 551, Bisha, 61922, Saudi Arabia.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):69-88. doi: 10.1007/s00210-024-03347-6. Epub 2024 Aug 5.

DOI:10.1007/s00210-024-03347-6
PMID:39102032
Abstract

Pituitary adenomas (PAs) are tumors originating in the pituitary gland, a small gland located at the base of the brain. They are the most common type of pituitary tumor, affecting approximately 1 in 10 people over their lifetime. Common symptoms include headaches, vision problems, hormonal imbalances, and weight changes. Treatment options depend on the type and size of the adenoma and may consist of medication, surgery, radiation therapy, or a combination. PAs are typically benign and slow-growing, but they can cause significant health issues if left untreated. Proper diagnosis and management by an experienced multidisciplinary team is important for achieving the best outcomes. Natural compounds like celastrol, curcumin, quercetin, apigenin, resveratrol, epigallocatechin gallate (EGCG), and genistein have shown the ability to inhibit cell growth, promote cell death, and suppress hormone activity in pituitary tumor cells, suggesting their potential as alternative or complementary treatments for PAs. MicroRNAs (miRNAs) are a kind of tiny RNA molecules that do not code for proteins and have a vital function in controlling gene expression. These 21-23 nucleotide-long molecules regulate gene expression by binding to complementary sequences in mRNA molecules, leading to mRNA degradation. miRNAs participate in a wide range of biological activities, including apoptosis, metastasis, differentiation, and proliferation. The research indicates that miRNAs play a crucial role in the pathogenesis, therapeutic approaches, diagnosis, and prognosis of PAs. This review article will provide a comprehensive analysis of the current understanding of the efficacy of naturally derived anti-cancer agents in the treatment of PAs. Furthermore, the study provides a comprehensive assessment of the miRNAs in PAs, their role in the development of PAs, and their potential application in the treatment of the condition.

摘要

垂体腺瘤(PAs)是起源于垂体的肿瘤,垂体是位于脑底部的一个小腺体。它们是最常见的垂体肿瘤类型,一生中约每10人中有1人会受其影响。常见症状包括头痛、视力问题、激素失衡和体重变化。治疗方案取决于腺瘤的类型和大小,可能包括药物治疗、手术、放射治疗或联合治疗。垂体腺瘤通常是良性的且生长缓慢,但如果不治疗,可能会导致严重的健康问题。由经验丰富的多学科团队进行正确的诊断和管理对于取得最佳治疗效果很重要。天然化合物如雷公藤红素、姜黄素、槲皮素、芹菜素、白藜芦醇、表没食子儿茶素没食子酸酯(EGCG)和染料木黄酮已显示出能够抑制垂体肿瘤细胞的生长、促进细胞死亡并抑制激素活性,表明它们作为垂体腺瘤替代或辅助治疗的潜力。微小RNA(miRNAs)是一类不编码蛋白质的微小RNA分子,在控制基因表达方面具有重要作用。这些长度为21 - 23个核苷酸的分子通过与mRNA分子中的互补序列结合来调节基因表达,导致mRNA降解。miRNAs参与广泛的生物学活动,包括细胞凋亡、转移、分化和增殖。研究表明,miRNAs在垂体腺瘤的发病机制、治疗方法、诊断和预后中起着关键作用。这篇综述文章将对目前对天然来源的抗癌药物治疗垂体腺瘤疗效的理解进行全面分析。此外,该研究对垂体腺瘤中的miRNAs、它们在垂体腺瘤发生发展中的作用以及它们在该疾病治疗中的潜在应用进行了全面评估。

相似文献

1
Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention.垂体腺瘤中基于天然产物和微小RNA的方法:揭示治疗干预措施
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):69-88. doi: 10.1007/s00210-024-03347-6. Epub 2024 Aug 5.
2
The emerging role of miRNAs in pituitary adenomas: From molecular signatures to diagnostic potential.微小 RNA 在垂体腺瘤中的新兴作用:从分子特征到诊断潜能。
Exp Cell Res. 2024 Oct 1;442(2):114279. doi: 10.1016/j.yexcr.2024.114279. Epub 2024 Oct 9.
3
MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior.垂体瘤中的 microRNAs 表达:与功能状态、病理特征和临床行为相关的差异。
J Endocrinol Invest. 2020 Jul;43(7):947-958. doi: 10.1007/s40618-019-01178-4. Epub 2020 Jan 14.
4
MicroRNAs in the human pituitary.人类垂体中的 microRNAs。
Endocr Pathol. 2011 Sep;22(3):134-43. doi: 10.1007/s12022-011-9167-6.
5
The Involvement of miRNAs in Pituitary Adenomas Pathogenesis and the Clinical Implications.miRNAs 参与垂体腺瘤的发病机制及其临床意义。
Eur Neurol. 2022;85(3):171-176. doi: 10.1159/000521388. Epub 2022 Jan 14.
6
MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas.微小 RNA 作为垂体腺瘤的非侵入性生物标志物和治疗剂。
Int J Mol Sci. 2020 Oct 2;21(19):7287. doi: 10.3390/ijms21197287.
7
Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas.侵袭性垂体腺瘤的分子诊断与药物治疗策略进展
Immun Inflamm Dis. 2024 Dec;12(12):e70098. doi: 10.1002/iid3.70098.
8
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.免疫治疗在难治性垂体腺瘤和垂体癌中的进展。
Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020.
9
MicroRNAs: Suggested role in pituitary adenoma pathogenesis.微小 RNA:在垂体腺瘤发病机制中的作用。
J Endocrinol Invest. 2013 Nov;36(10):889-95. doi: 10.1007/BF03346759.
10
Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas.下一代 microRNA 测序揭示了不同类型垂体腺瘤中的独特表达模式。
Endocr J. 2019 Aug 29;66(8):709-722. doi: 10.1507/endocrj.EJ18-0487. Epub 2019 Apr 26.

本文引用的文献

1
Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets.以表没食子儿茶素没食子酸酯(EGCG)靶向癌症特征:机制基础和治疗靶点。
Molecules. 2024 Mar 20;29(6):1373. doi: 10.3390/molecules29061373.
2
Quercetin as a Therapeutic Product: Evaluation of Its Pharmacological Action and Clinical Applications-A Review.槲皮素作为一种治疗产品:其药理作用及临床应用的评估——综述
Pharmaceuticals (Basel). 2023 Nov 20;16(11):1631. doi: 10.3390/ph16111631.
3
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
催乳素分泌型垂体腺瘤的诊断和治疗:垂体学会国际共识声明。
Nat Rev Endocrinol. 2023 Dec;19(12):722-740. doi: 10.1038/s41574-023-00886-5. Epub 2023 Sep 5.
4
The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment.没食子儿茶素-3-没食子酸酯(EGCG)在乳腺癌治疗中的潜在作用。
Int J Mol Sci. 2023 Jun 27;24(13):10737. doi: 10.3390/ijms241310737.
5
Tumor-Associated Fibroblast-Derived Exosomal circDennd1b Promotes Pituitary Adenoma Progression by Modulating the miR-145-5p/ONECUT2 Axis and Activating the MAPK Pathway.肿瘤相关成纤维细胞衍生的外泌体环状Dennd1b通过调节miR-145-5p/ONECUT2轴并激活丝裂原活化蛋白激酶(MAPK)途径促进垂体腺瘤进展。
Cancers (Basel). 2023 Jun 27;15(13):3375. doi: 10.3390/cancers15133375.
6
Cushing Syndrome: A Review.库欣综合征:综述。
JAMA. 2023 Jul 11;330(2):170-181. doi: 10.1001/jama.2023.11305.
7
microRNAs in action: biogenesis, function and regulation.微小 RNA 在行动中:生物发生、功能和调节。
Nat Rev Genet. 2023 Dec;24(12):816-833. doi: 10.1038/s41576-023-00611-y. Epub 2023 Jun 28.
8
A spotlight on the interplay of signaling pathways and the role of miRNAs in osteosarcoma pathogenesis and therapeutic resistance.聚焦信号通路的相互作用以及 miRNA 在骨肉瘤发病机制和治疗耐药中的作用。
Pathol Res Pract. 2023 May;245:154442. doi: 10.1016/j.prp.2023.154442. Epub 2023 Apr 6.
9
The interplay of signaling pathways with miRNAs in cholangiocarcinoma pathogenicity and targeted therapy.信号通路与微小 RNA 在胆管癌发病机制和靶向治疗中的相互作用。
Pathol Res Pract. 2023 May;245:154437. doi: 10.1016/j.prp.2023.154437. Epub 2023 Apr 5.
10
The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update.槲皮素对血液癌、前列腺癌和肺癌的潜在抗癌作用:最新研究进展。
Front Immunol. 2023 Feb 28;14:1077531. doi: 10.3389/fimmu.2023.1077531. eCollection 2023.